Rajesh Krishnan - 21 Feb 2023 Form 4 Insider Report for Oncternal Therapeutics, Inc.

Role
Chief Technology Officer
Signature
/s/ Chase C. Leavitt, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
21 Feb 2023
Net transactions value
$0
Form type
4
Filing time
23 Feb 2023, 19:00:44 UTC
Previous filing
05 Jan 2023
Next filing
05 Jul 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ONCT Stock Option Award $0 +220,000 $0.000000 220,000 21 Feb 2023 Common Stock 220,000 $0.9600 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the stock option vest on first anniversary of the date of grant, and the remaining shares subject to the option vest in 36 equal monthly installments, subject to the recipient's continued employment or service with the Issuer on each such date.